Considering that AR-independent and neuroendocrine-like prostate cancers are more likely to receive platinum treatment, our study specifically addresses the clinical and biological relevance of BIRC5/survivin in this disease context. The gene discussed is BIRC5; the disease is Familial prostate cancer.